Browse the evidence

GLP-1 receptor agonists slow renal disease progression and reduce albuminuria in patients with diabetic kidney disease, although evidence is less robust than for SGLT2 inhibitors.

If you have diabetic kidney disease, GLP-1 receptor agonists may help slow kidney damage and reduce protein in your urine. While there is less data on their kidney benefits compared to SGLT2 inhibitors, they are still considered valuable. Discuss with your doctor if they are appropriate for you, especially if you have cardiovascular risks.

Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.

While effective, orforglipron often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (12 mg and above). These side effects are the main reason people stop taking the medication. Patients should be aware that higher doses provide more weight loss but also carry a higher risk of stopping treatment due to discomfort. Starting at a lower dose and titrating slowly may help manage these side effects.

Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).

If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.

The enteric nervous system (ENS) directly senses luminal nutrients (glucose, fatty acids, amino acids) via specific receptors and ion channels on enteric neurons, independent of enteroendocrine cell intermediaries.

Your gut has its own nervous system that directly senses nutrients like glucose and fats, not just through hormones but through direct neural pathways. This 'second brain' communicates with your central brain to regulate hunger and satiety. Understanding this can help explain why certain foods trigger immediate physiological responses and why gut health is crucial for metabolic regulation.

GLP-1 release is significantly blunted or absent in morbidly obese individuals and those with type 2 diabetes, contributing to dysregulated nutrient sensing and appetite control.

In obesity and type 2 diabetes, the body's natural production of GLP-1, a hormone that helps you feel full, is often blunted. This makes it physiologically harder to regulate food intake. Treatments that mimic GLP-1 (like GLP-1 agonists) work by restoring this signal, highlighting the importance of this pathway in weight management.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), restores GLP-1 secretion by rapidly delivering nutrients to the distal gut where L-cells are concentrated, leading to increased satiety and weight loss.

Bariatric surgery, like RYGB, works partly by changing how your gut hormones respond to food. By delivering nutrients to the distal gut faster, it triggers a surge in GLP-1, a hormone that promotes satiety. This hormonal reset is a key factor in the weight loss achieved after surgery.

GLP-1 receptor agonists significantly delay gastric emptying and increase residual gastric content, but do not significantly increase the absolute risk of pulmonary aspiration in standard endoscopic procedures.

If you take GLP-1s (like Ozempic or Wegovy) for an endoscopy, expect your stomach to empty slower, but know the risk of lung infection is very low. You likely do not need to stop your medication unless you have specific symptoms or high-risk procedures. Follow extended clear-liquid fasting instructions and use gastric ultrasound if available to ensure safety.

GLP-1 receptor agonists impair colonic preparation and delay capsule transit, increasing the likelihood of inadequate bowel cleansing and the need for repeat colonoscopies.

If you take GLP-1s for a colonoscopy, your bowel prep might be less effective than usual. You may need a more intensive prep regimen (like extended clear liquids or additional laxatives) to ensure the doctor can see clearly. This is common and manageable.

Pharmacological inhibition of angiotensin-converting enzyme (ACE) using enalapril (20 mg/day) during 8 weeks of high-intensity training significantly attenuates exercise-induced increases in lean body mass in healthy adults, while peripheral muscle adaptations and aerobic performance remain unaffected.

If you are taking ACE inhibitors (like enalapril or lisinopril) for blood pressure, be aware that these medications may blunt your muscle growth potential compared to not taking them. This does not mean you cannot build strength or endurance, but your muscle mass gains may be reduced. Focus on consistent training and nutrition, and consult your doctor before making any medication changes.

The ACE I/D genotype is a poor predictor of actual ACE enzyme activity and downstream exercise adaptations because it is in linkage disequilibrium with functional variants and does not consistently correlate with circulating Angiotensin II levels.

Do not rely solely on genetic testing (like ACE I/D) to predict your athletic potential or training response. These tests are often poor predictors of actual performance or muscle growth. Instead, focus on consistent training, proper nutrition, and recovery. If you are curious about your biology, direct measurement of enzyme activity (phenotyping) is more informative than genetic markers alone.

Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.

Stop relying on willpower and calorie counting alone to cure obesity. Your body is biologically fighting to keep its weight at a higher 'set point' through hunger hormones and slowed metabolism. This is not your fault. To achieve lasting weight loss, you likely need medical or surgical interventions that override these biological defenses, as lifestyle changes alone will eventually trigger a rebound effect.

Intracerebroventricular administration of the GLP-1 receptor agonist Exendin-4(1-32)K-capric acid (Ex-4c) suppresses food intake and body weight gain in mice by directly activating arcuate pro-opiomelanocortin (POMC) neurons.

This research identifies that a specific GLP-1 agonist (Ex-4c) reduces food intake by directly activating POMC neurons in the hypothalamus. The mechanism involves the closure of KATP channels via PKA-dependent signaling. While this is preclinical data in mice, it supports the broader class of GLP-1 agonists used for obesity treatment by confirming a central neural mechanism involving appetite suppression.

Adherence to a vegan diet increases circulating glycine levels despite lower dietary intake, mediated by the reduction of the gut pathobiont Bilophila wadsworthia and its glycine reductase pathway activity.

If you switch to a vegan diet, your body may naturally increase its levels of glycine, an amino acid linked to better insulin sensitivity and metabolic health. This happens not because you eat more glycine, but because your gut bacteria change to stop consuming it. You don't need to supplement glycine; simply adhering to a whole-food vegan diet appears to trigger this beneficial metabolic shift.

Bariatric surgery induces rapid hormonal changes (increased GLP-1, PYY, decreased ghrelin) and bile acid signaling that drive early satiety and metabolic improvements, independent of caloric restriction.

Bariatric surgery works by changing your body's hormones, not just by making your stomach smaller. You will likely feel full faster and have less hunger due to increased GLP-1 and PYY and decreased ghrelin. This biological shift supports your ability to stick to dietary changes.

Enobosarm increases lean body mass but fails to deliver consistent, clinically meaningful functional gains (e.g., stair-climb power) in cancer cachexia patients, leading to regulatory rejection.

Enobosarm was tested for cancer cachexia and successfully increased muscle mass, but it did not improve physical function enough to gain FDA approval. This highlights that muscle size alone does not guarantee functional improvement in sick populations.

S-309309, a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2), demonstrates acceptable safety and tolerability in healthy adults with or without obesity, with no clinically meaningful differences in pharmacokinetics between obese and non-obese individuals.

S-309309 is an experimental oral medication that inhibits MGAT2 to potentially aid weight management. Early trials show it is safe and well-tolerated in both obese and non-obese adults, with no significant drug interactions or cardiac effects observed at tested doses. It is not yet approved for general use.

Tirzepatide improves renal outcomes, including reducing the risk of macroalbuminuria and slowing the decline in estimated glomerular filtration rate (eGFR), in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about kidney health, tirzepatide not only helps control blood sugar and weight but also offers significant protection for your kidneys, reducing the risk of serious renal complications compared to insulin therapy.

Use of GLP-1 receptor agonists is not associated with an increased risk of gastrointestinal cancers and may be associated with reduced risks of colorectal and liver cancers.

Current evidence from large randomized trials indicates that GLP-1 receptor agonists do not increase the risk of gastrointestinal cancers. In fact, they may be associated with a reduced risk of colorectal and liver cancers, particularly in older and obese patients. While these findings are reassuring, cancer was often a secondary endpoint, so long-term monitoring remains important.

The indiscriminate use of tirzepatide for aesthetic purposes and the circulation of unregistered products significantly increase the risk of severe adverse events, including gastrointestinal issues, pancreatitis, and renal failure, while compromising public health surveillance.

Using tirzepatide without a doctor's supervision, especially for aesthetic reasons, carries serious risks like pancreatitis and kidney failure. Unregistered versions from informal markets may be fake or unsafe. Always use this medication under medical guidance with a legitimate prescription.

Disruption of the paracrine regulatory network within pancreatic islets—specifically the loss of somatostatin-mediated inhibition of glucagon and insulin-mediated suppression of glucagon—exacerbates hyperglycemia in Type 2 Diabetes.

Managing diabetes effectively requires looking beyond just insulin levels. If you have Type 2 Diabetes, your body's internal hormonal balance—specifically the signals that tell your liver to release sugar (glucagon) and the signals that tell it to stop (somatostatin)—may be broken. This means that even if you are managing insulin, your blood sugar might remain high because your body is still receiving 'release sugar' signals it shouldn't be. Modern therapies increasingly target these other hormones to restore the full balance.

Postprandial administration of para-tyramine-O-sulphate (pTOS) acts as a conserved anorexigenic gut-brain signal that suppresses food intake and body weight in mice by activating ventromedial hypothalamus (VMH) neurons, without affecting energy expenditure or gastric emptying.

This research identifies pTOS, a metabolite produced by gut bacteria from dietary tyrosine, as a natural signal that tells your brain to stop eating. In mice, supplementing with pTOS reduced food intake and body weight without changing how much energy they burned or how fast their stomach emptied. The effect works by activating specific neurons in the hypothalamus. While human studies show pTOS levels rise after meals, the clinical application for weight loss is still in early stages, particularly for those with diabetes.

Caloric restriction (14% reduction for 2 years) reduces circulating C3a levels in humans, independent of BMI changes, thereby suppressing complement-mediated inflammation.

Adopting a moderate caloric restriction (around 14% less than maintenance) for an extended period (e.g., 2 years) can significantly lower specific inflammatory markers like C3a in the blood. This reduction happens regardless of how much weight you lose, suggesting that the act of eating less directly modulates your immune system to reduce age-related inflammation.